Back

The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure

28 August 2022 (10:15 - 10:55)
Organised by:
Congress Presentation Part of: Anticoagulant therapy: real world use and clinical challenges Anticoagulants ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Jolanta Siller-Matula

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
Mr M. Grymonprez (Gent, BE)
Abstract Slides
Presentation thumbnail
Oral anticoagulation in patients with atrial fibrillation and stage IV and V chronic kidney disease: a systematic review and meta-analysis
Doctor A. Miranda-Arboleda (Boston, US)
Abstract Slides
Presentation thumbnail
Potentially inappropriate prescribing and its demographic and clinical correlates in older adults with atrial fibrillation: a population-based study
Ms C. Amrouch (Ghent, BE)
Abstract Slides
Presentation thumbnail
The effect of eplerenone on the disease onset and progression of phospholamban cardiomyopathy in presymptomatic mutation carriers: results of the i-PHORECAST trial
Mr R. De Brouwer (Groningen, NL)
Abstract Slides

Access the full session

Session thumbnail
Anticoagulant therapy: real world use and clinical challenges

The Event

Event poster

ESC Congress 2022

28 August 2022 10:15 CET
You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Presentation
Contemporary thrombosis management -- state of the state

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources